Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans-Joerg Fugel

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Frontiers in Pharmacology|October 23, 2012
Stratified medicine and reimbursement issuesHans-Joerg Fugel, Mark Nuijten, Maarten Postma
Journal of Medical Economics|March 25, 2014
The application of economics concepts to stratified medicine--use of health economics data to support market access for stratified medicine interventionsHans-Joerg Fugel, Mark Nuijten, Eric Faulkner
New Biotechnology|September 25, 2016
Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environmentHans-Joerg Fugel, Mark Nuijten, Maarten Postma
BMC Health Services Research|October 10, 2014
An economic assessment of embryo diagnostics (Dx) - the costs of introducing non-invasive embryo diagnostics into IVF standard treatment practicesHans-Joerg Fugel, Mark Connolly, Mark Nuijten
Frontiers in Pharmacology|June 1, 2016
Economic Evaluation in Stratified Medicine: Methodological Issues and ChallengesHans-Joerg Fugel, Mark Nuijten, Maarten Postma, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Frontiers in Pharmacology|October 23, 2012
Stratified medicine and reimbursement issuesHans-Joerg Fugel, Mark Nuijten, Maarten Postma
Journal of Medical Economics|March 25, 2014
The application of economics concepts to stratified medicine--use of health economics data to support market access for stratified medicine interventionsHans-Joerg Fugel, Mark Nuijten, Eric Faulkner
New Biotechnology|September 25, 2016
Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environmentHans-Joerg Fugel, Mark Nuijten, Maarten Postma
BMC Health Services Research|October 10, 2014
An economic assessment of embryo diagnostics (Dx) - the costs of introducing non-invasive embryo diagnostics into IVF standard treatment practicesHans-Joerg Fugel, Mark Connolly, Mark Nuijten
Frontiers in Pharmacology|June 1, 2016
Economic Evaluation in Stratified Medicine: Methodological Issues and ChallengesHans-Joerg Fugel, Mark Nuijten, Maarten Postma, et al.
Pageof 1